dc.contributor.author | Prat, A | |
dc.contributor.author | Lluch, A | |
dc.contributor.author | Turnbull, AK | |
dc.contributor.author | Dunbier, AK | |
dc.contributor.author | Calvo, L | |
dc.contributor.author | Albanell, J | |
dc.contributor.author | de la Haba-Rodríguez, J | |
dc.contributor.author | Arcusa, A | |
dc.contributor.author | Chacón, JI | |
dc.contributor.author | Sánchez-Rovira, P | |
dc.contributor.author | Plazaola, A | |
dc.contributor.author | Muñoz, M | |
dc.contributor.author | Paré, L | |
dc.contributor.author | Parker, JS | |
dc.contributor.author | Ribelles, N | |
dc.contributor.author | Jimenez, B | |
dc.contributor.author | Bin Aiderus, AA | |
dc.contributor.author | Caballero, R | |
dc.contributor.author | Adamo, B | |
dc.contributor.author | Dowsett, M | |
dc.contributor.author | Carrasco, E | |
dc.contributor.author | Martín, M | |
dc.contributor.author | Dixon, JM | |
dc.contributor.author | Perou, CM | |
dc.contributor.author | Alba, E | |
dc.date.accessioned | 2017-07-19T15:34:40Z | |
dc.date.issued | 2017-06 | |
dc.identifier.citation | Clinical cancer research : an official journal of the American Association for Cancer Research, 2017, 23 (12), pp. 3035 - 3044 | |
dc.identifier.issn | 1078-0432 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/724 | |
dc.identifier.eissn | 1557-3265 | |
dc.identifier.doi | 10.1158/1078-0432.ccr-16-2092 | |
dc.description.abstract | Purpose: Hormone receptor-positive (HR + ) breast cancer is clinically and biologically heterogeneous, and subgroups with different prognostic and treatment sensitivities need to be identified. Experimental Design: Research-based PAM50 subtyping and expression of additional genes was performed on 63 patients with HR + /HER2 - disease randomly assigned to neoadjuvant multiagent chemotherapy versus endocrine therapy in a phase II trial. The biology associated with treatment response was used to derive a PAM50-based chemoendocrine score (CES). CES's predictive ability was evaluated in 4 independent neoadjuvant data sets ( n = 675) and 4 adjuvant data sets ( n = 1,505). The association of CES, intrinsic biology, and PAM50 risk of relapse (ROR) was explored across 6,007 tumors. Results: Most genes associated with endocrine sensitivity were also found associated with chemotherapy resistance. In the chemotherapy test/validation data sets, CES was independently associated with pathologic complete response (pCR), even after adjusting for intrinsic subtype. pCR rates of the CES endocrine-sensitive (CES-E), uncertain (CES-U), and chemotherapy-sensitive (CES-C) groups in both data sets combined were 25%, 11%, and 2%, respectively. In the endocrine test/validation data sets, CES was independently associated with response. Compared with ROR, >90% of ROR-low and ROR-high tumors were identified as CES-E and CES-C, respectively; however, each CES group represented >25% of ROR-intermediate disease. In terms of survival outcome, CES-C was associated with poor relapse-free survival in patients with ROR-intermediate disease treated with either adjuvant endocrine therapy only or no adjuvant systemic therapy, but not in patients treated with (neo)adjuvant chemotherapy. Conclusions: CES is a genomic signature capable of estimating chemoendocrine sensitivity in HR + breast cancer beyond intrinsic subtype and risk of relapse. Clin Cancer Res; 23(12); 3035-44. ©2016 AACR . | |
dc.format | Print-Electronic | |
dc.format.extent | 3035 - 3044 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.rights.uri | https://www.rioxx.net/licenses/all-rights-reserved | |
dc.subject | Humans | |
dc.subject | Breast Neoplasms | |
dc.subject | Neoplasm Recurrence, Local | |
dc.subject | Recurrence | |
dc.subject | Receptor, erbB-2 | |
dc.subject | Neoplasm Proteins | |
dc.subject | Receptors, Estrogen | |
dc.subject | Receptors, Progesterone | |
dc.subject | Antineoplastic Agents, Hormonal | |
dc.subject | Prognosis | |
dc.subject | Neoadjuvant Therapy | |
dc.subject | Gene Expression Regulation, Neoplastic | |
dc.subject | Aged | |
dc.subject | Middle Aged | |
dc.subject | Female | |
dc.title | A PAM50-Based Chemoendocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of Relapse. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2016-11-07 | |
rioxxterms.versionofrecord | 10.1158/1078-0432.ccr-16-2092 | |
rioxxterms.licenseref.uri | https://www.rioxx.net/licenses/all-rights-reserved | |
rioxxterms.licenseref.startdate | 2017-06 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Clinical cancer research : an official journal of the American Association for Cancer Research | |
pubs.issue | 12 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research/Endocrinology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Endocrinology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Endocrinology/Endocrinology (hon.) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research/Endocrinology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Endocrinology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Endocrinology/Endocrinology (hon.) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.publication-status | Published | |
pubs.volume | 23 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Endocrinology | en_US |
dc.contributor.icrauthor | Dowsett, Mitch | |
dc.contributor.icrauthor | Marsden, | |